伏立康唑联合小剂量糖皮质激素治疗儿童隐球菌性脑膜炎:2例报道并文献复习

中国真菌学杂志　 2010, Vol. 5 　Issue (4): 214-217.

伏立康唑联合小剂量糖皮质激素治疗儿童隐球菌性脑膜炎:2例报道并文献复习

陈裕充, 雷文知, 都琳, 杨雅骊, 陈江汉, 顾菊林, 温海

第二军医大学长征医院皮肤科, 上海, 200003

收稿日期:2010-05-15 出版日期:2010-08-28 发布日期:2010-08-28
通讯作者: 顾菊林,E-mail:wujgj@l126.com;温海,E-mail:wenhai98@sohu.com E-mail:wujgj@l126.com;wenhai98@sohu.com
作者简介:陈裕充,男(汉族),博士,主治医师.E-mail:cyuchong@yahoo.com.cn
基金资助:
国家自然科学基金(30972817)

Voriconazole with low dose of glucocorticosteroid for the treatment of cryptococcal meningitis in children:2 case reports and literature review

CHEN Yu-chong, LEI Wen-zhi, DU lin, YANG Ya-li, CHEN Jiang-han, GU Ju-lin, WEN Hai

Department of Dermatology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China

Received:2010-05-15 Online:2010-08-28 Published:2010-08-28

摘要/Abstract

摘要： 目的探讨伏立康唑联合小剂量糖皮质激素对儿童隐球菌性脑膜炎的疗效。方法分析2例采用伏立康唑联合小剂量糖皮质激素治疗的儿童隐球菌性脑膜炎病例并进行相关文献复习。结果患儿经治疗后头痛等症状消失,颅内压逐渐下降至正常水平,脑脊液蛋白水平明显下降并稳定。结论伏立康唑联合小剂量糖皮质激素能迅速有效地控制临床症状,使用方便、副作用小,可作为儿童隐球菌性脑膜炎诱导治疗的一种选择。

关键词: 隐球菌性脑膜炎, 儿童, 伏立康唑, 糖皮质激素

Abstract: Objective To explore the effect of voriconazole and glucocorticosteroid for the treatment of cryptococcal meningitis in children.Methods Manifestation,intracranial pressure and protein production in cerebrospinal fluid of the 2 patients with cryptococcal meningitis after the treatment were analyzed.Results The intracranial pressure and protein production in cerebrospinal fluid decreased and stabilized in normal range after 4-week treatment.Conclusions Voriconazole combinatied with low dose of glucocorticosteroid was effective for cryptococcal meningitis in children with convenience and fewer side effects.

Key words: cryptococcal meningitis, children, voriconazole, glucocorticosteroid

中图分类号:

R725.1

陈裕充, 雷文知, 都琳, 杨雅骊, 陈江汉, 顾菊林, 温海. 伏立康唑联合小剂量糖皮质激素治疗儿童隐球菌性脑膜炎:2例报道并文献复习[J]. 中国真菌学杂志, 2010, 5(4): 214-217.

CHEN Yu-chong, LEI Wen-zhi, DU lin, YANG Ya-li, CHEN Jiang-han, GU Ju-lin, WEN Hai. Voriconazole with low dose of glucocorticosteroid for the treatment of cryptococcal meningitis in children:2 case reports and literature review[J]. Chinese Journal of Mycology, 2010, 5(4): 214-217.

参考文献

[1] McCahy KM,Morgan J,Wannemuehler KA.Populationbased surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence[J] AIDS,2006,20(17):2199-2206.
[2] Morgan J,McCarthy KM,Gould S.Cryptococcus gattii infection:characteristics and epidemiology of cases identified in a South African province with high HIV sero prevalence,2002-2004[J] Clin Infect Dis,2006,43(8):1077-1080.
[3] 徐楠,朱元杰,陈江汉,等.儿童隐球菌性脑膜炎临床分析[J] 中国真菌学杂志,2009,4(1):24-25.
[4] 顾菊林,温海,廖万清.儿童隐球菌性脑膜炎(附8例报告)[J] 第二军医大学学报,2002.23(12):1344.
[5] Perfect JR,Dismukes WE,Dromer F.Clinical practice guidelines for the management of cryptoceccal disease:2010 update by the Infectious Diseases Society of America[J] Clin Infect Dis,2010,50(3):291-322.
[6] Pfaller MA,J Zhang,Messer SA.In vitro activities of voriconazole,fluconazole,and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa[J] Antimicrob Agents Chemother,1999,43(1):169-171.
[7] Pfaller MA,Messer S A,Boyken L.Global trends in the antifungal susceptibility of Cryptococcus neoformans(1990 to2004)[J] J Clin Microbiol,2005,43(5):2163-2167.
[8] Pfaller MA,Messer SA,Boyken L.In vitro activities of vericonazole,posaconazole,and fluconazole against 4,169 clinical isolates of Candida spp.and Crypwcoccus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program[J] Diagn Microbiol Infect Dis,2004,48(3):201-205.
[9] Pfaller MA,Diekema DJ,Gibbs DL.Results from the ARTEMIS DISK global antifungal surveillance study,1997 to2007:10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing[J] J Clin Microbiol,2009,47(1):117-123.
[10] Yildiran ST,Fothergill AW,Sutton DA.In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole,voriconazole and pesaconazole(SCH56592)[J] Mycoses,2002,45(9-10):378-383.
[11] Van Duin D,Clesre W,Zaragoza O.Effects of voriconazole on Cryptococcus neoformans[J] Antimicrob Agents Chemother,2004,48(6):2014-2020.
[12] Sabbatanil S,Manfredil R,Pavoni M.Voriconazole proves effective in long-term treatment of a cerebral cryptoesccoma in a chronic nephropathic HIV-nogative patient,after fluconazole failure[J] Mycopathoiogia,2004,158(2):165-171.
[13] 沈银忠,卢洪洲,齐唐凯,等.两性霉素B联合氟胞嘧啶与伏立康唑治疗艾滋病合并隐球菌脑膜炎的临床回顾性研究[J] 中国真菌学杂志,2009,4(6):338-342.
[14] 李玲,水泉样,尚世强,等.地塞米松治疗与细菌性脑膜炎脑源性神经营养因子及其受体基因表达的关系[J] 中华传染病杂志,2003,21(2):128-131.
[15] Thwaites GE,Nguyen DB,Nguyen HD.Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults[J] N Engl J Med,2004,351(17):1741-1751.
[16] de Vries TW,Rettier BL,Visserman H.The influence of inhaled corticesteroids and spacer devices on the growth of respiratory pathogenic microorganisms[J] Am J Infect Control,2009,37(3):237-240.